Company intelligence / Profile preview
Neurotech Pharmaceuticals
Cumberland, Rhode Island, United Statesneurotechpharmaceuticals.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Neurotech’s ECT platform has demonstrated the ability to deliver therapeutic proteins directly into the eye over extended periods. Their lead candidate targets macular telangiectasia type 2 and has shown promise in protecting against progressive vision loss by releasing ciliary neurotrophic factor. Clinical research is ongoing, with evidence of long-term safety and efficacy emerging from trials.
- Therapeutic areas
- Ophthalmology
- Modalities
- Encapsulated Cell Therapy (ECT) PlatformBiologicCell therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Neurotech Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurotech Pharmaceuticals.